Recent discoveries in GPCR signaling have elucidated multiple critical roles of beta-arrestins which are scaffolding proteins that regulate GPCR internalization and signaling. Beta-arrestins are promising to clinical targets, because mice with a knockout of a single beta-arrestin have no overt phenotype, while dual knockout of beta-arrestin1 and beta-arrestin2 is lethal. Also, bladder cancer cells express elevated levels of beta-arrestin2 and one of its activators, the thromboxane-beta GPCR. This increase correlates with a poor clinical prognosis and suggests beta-arrestin2 as a bladder cancer target. Although GPCRs are a major clinical target, to date there are no small molecule regulators for beta-arrestins. Using high performance docking on the NICS Kraken supercomputer, we have conducted virtual screening of a 1.4 million compound library and identified ~250 potential beta-arrestin2 inhibitors. We then created and validated a high throughput and high-content screen targeting GPCR/ B-arrestin2 interactions and tested 61 predicted inhibitory compounds, 15 of which decreased receptor internalization by >40%, validating our discovery strategy. We will complete the screening of all the predicted inhibitors and carry out lead optimization to increase their potency and selectivity for beta-arrestin2. The resulting first selective inhibitors of betaarrestin2 will be used to determine their effect and selectivity on downstream GPCR signaling events in model cell systems. We will also test our beta-arrestin2 inhibitor for anticancer activity using cell based and animal models of bladder cancer. The success of this study will warrant the development of beta-arrestin2 inhibitors as therapeutic agents for bladder cancer and other diseases associated with aberrant betaarrestin- mediated signal transduction.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-A (C1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of South Carolina at Columbia
United States
Zip Code
Varadaraj, Archana; Magdaleno, Carina; Mythreye, Karthikeyan (2018) Deoxycholate Fractionation of Fibronectin (FN) and Biotinylation Assay to Measure Recycled FN Fibrils in Epithelial Cells. Bio Protoc 8:
Liu, Changlong; Banister, Carolyn E; Weige, Charles C et al. (2018) PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids. Proc Natl Acad Sci U S A 115:E5066-E5075
Yu, Jin; Zhu, Hong; Taheri, Saeid et al. (2018) Impact of nutrition on inflammation, tauopathy, and behavioral outcomes from chronic traumatic encephalopathy. J Neuroinflammation 15:277
Jenkins, Laura M; Horst, Ben; Lancaster, Carly L et al. (2018) Dually modified transmembrane proteoglycans in development and disease. Cytokine Growth Factor Rev 39:124-136
Alam, Amer; K√ľng, Raphael; Kowal, Julia et al. (2018) Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A 115:E1973-E1982
Liang, Jiaxin; Chen, Mengqian; Hughes, Daniel et al. (2018) CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases. Cancer Res 78:6594-6606
Chukwurah, Evelyn; Patel, Rekha C (2018) Stress-induced TRBP phosphorylation enhances its interaction with PKR to regulate cellular survival. Sci Rep 8:1020
Singh, Priyanka; Jenkins, Laura M; Horst, Ben et al. (2018) Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis. Cancer Res 78:2978-2989
Wyatt, Michael D; Reilly, Nicole M; Patel, Shikha et al. (2018) Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells. Environ Mol Mutagen 59:38-48
Serrao, Anne; Jenkins, Laura M; Chumanevich, Alexander A et al. (2018) Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene 37:4792-4808

Showing the most recent 10 out of 49 publications